Skip to main content

Table 3 Comparison of atorvastatin for the prophylaxis of aGVHD based on two representative studies

From: Management of dyslipidemia after allogeneic hematopoietic stem cell transplantation

  Study 1 (Ref. 53) Study 2 (Ref. 24)
First author Yvonne A.Efebera Mehdi Hamadani
Journal Biology of Blood and Marrow Transplantation Journal of Clinical Oncology
Study time Mar 2012-Jan 2014 Sep 2010-Oct 2012
Publication year 2016 2013
Number of participants 50 patient-donor pairs 30 patient-donor pairs
Median age
Recipient 51 54.5
Donor 50 52.5
Control group Historical control subjects (n = 96) Historial data from the same institution
Conditioning regimen
Myeloablative conditioning Fludarabine/busulfan (15%)
TBI/etoposide (10%)
TBI/cyclophosphamide (5%)
Busulfan/cyclophosphamide (6.6%)
Fludarabine/busulfan (36.6%)
Reduced-intensity conditioning Fludarabine/busulfan (65%)
Fludarabine/melphalan (5%)
Fludarabine/busulfan (56.6%)
Diagnosis AML (30%)
NHL + HL (36.6%)
MDS (10%)
PMF (6.6%)
Others (16.6%)
AML (33%)
NHL + HL (15%)
ALL (15%)
CML(8%)
MDS/CMML (18%)
Others (13%)
GVHD prophylaxis Methotrexate and tacrolimus Methotrexate and tacrolimus
Median CD34 + cell infused (× 106 /kg) 5.90 4.25
Median CD3 + cells infused (× 108 /kg) 2.65 3.30
Dose of atorvastatin 40 mg/day 40 mg/day
Timing of atorvastatin application (before stem cell collection) 14 days Range from 14 to 28 days
Infection CMV, EBV, BKV, fungal and bacterial infections did not differ significantly from the controls Three patients (10%) developed CMV reactivation and BK-viral hemorrhagic cystitis
Immune reconstitution NK and Treg cells were fewer than the control No statistical significance
Cytokines Elevation of RANTES Elevation of IL-10
Grades 2–4 GVHD at + 100 and + 180 days (%) 30% and 40%, respectively 3.3% and 11.1%, respectively
Gades 2–4 GVHD in control group at + 100 days (%) 28% Ranged from 30 to 35%
1 year NRM (%) 5.5% 9.8%
1 year PFS (%) 54% 65%
1 year OS (%) 82% 74%
Conclusion Negative result Positive result
  1. Abbreviations: AML Acute myelogenous leukemia, ALL Acute lymphocytic leukemia, CML Chronic myelogenous leukemia, HL Hodgkin lymphoma, NHL Non-Hodgkin lymphoma, MDS Myelodysplastic syndrome, CMV Cytomegalovirus, EBV Epstein-Barr virus, BKV BK virus, PMS Primary myelofibrosis, NRM Non relapse mortality, PFS Progression-free survival, OS Overall survival